XML 37 R26.htm IDEA: XBRL DOCUMENT v3.22.1
Segment Information
 3 Months Ended
Mar. 31, 2022
Segment Reporting [Abstract]  
Segment Information Segment Information
The Company operates its business and reports its results through three operating and reportable segments: dispensary, patient services, and clinical trials & other in accordance with ASC 280. See Note 2 for a summary of the Company’s policy on segment information.
Summarized financial information for the Company’s segments is shown in the following tables:
(in thousands)Three Months Ended March 31,
20222021
Revenue
Patient services$35,057 $29,622 
Dispensary18,679 17,618 
Clinical trials & other1,425 1,340 
Consolidated revenue55,161 48,580 
Direct costs
Patient services27,378 23,086 
Dispensary15,324 15,123 
Clinical trials & other137 169 
Total segment direct costs42,839 38,378 
Depreciation expense
Patient services250 127 
Dispensary— — 
Clinical trials & other47 29 
Total segment depreciation expense297 156 
Amortization of intangible assets
Patient services621 560 
Dispensary— — 
Clinical trials & other53 53 
Total segment amortization674 613 
Operating income
Patient services6,808 5,849 
Dispensary3,355 2,495 
Clinical trials & other1,188 1,089 
Total segment operating income11,351 9,433 
Selling, general and administrative expense29,806 11,178 
Non-segment depreciation and amortization16 8 
Total consolidated operating loss$(18,471)$(1,753)
(in thousands)March 31, 2022December 31, 2021
Assets   
Patient services$47,086 $44,223 
Dispensary6,172 4,277 
Clinical trials & other13,717 14,504 
Non-segment assets139,537 140,435 
Total assets$206,512 $203,439